Afystyla
Product Specs | Description |
---|---|
Manufacturer Name | CSL Behring |
Description | AFYSTYLA®, Antihemophilic Factor (Recombinant), Single Chain, is indicated in adults and children with hemophilia A (congenital Factor VIII deficiency) |
Indications for Adults: | |
Control and Prevention of Bleeding Episodes | Yes |
Perioperative Management | Yes |
Routine Prophylaxis to Prevent or Reduce the Frequency of Bleeding Episodes | Yes |
Indications for Children: | |
Control and Prevention of Bleeding Episodes | Yes |
Perioperative Management | Yes |
Routine Prophylaxis to Prevent or Reduce the Frequency of Bleeding Episodes | Yes |
Contraindications Nutrient in Cell Culture | Do not use in patients who have had lifethreatening hypersensitivity reactions, including anaphylaxis to AFYSTYLA or its excipients, or hamster proteins. |
Stabilizer in Final Formulation | Polysorbate 80, calcium chloride, sodium chloride, sucrose, L-Histidine |
Viral Safety Process | Purified by a controlled multi-step process including two virus reduction steps complementing each other in their mode of action. No human or animal derived proteins are used in the purification or formulation processes. |
Product Half-Life | ≥18yrs: 14.2 (26.0) hours 12 to < 18yrs: 14.3 (33.3) hours 6 to < 12yrs: 10.2 (19.4) hours 0 to < 6yrs: 10.4 (28.7) hours |
Product Recovery Percentage Mean incremental recovery IR (IU/dL per IU/kg) | ≥18 yrs: 2.00 (20.8) 12 to <18yrs: 1.69 (24.8) 6 to <12 yrs: 1.66 (19.7) 0 to <6yrs: 1.60 (21.1) |
Storage Requirements/Shelf Life |
|
Nominal Vial Size & Diluent Volume | 250, 500, 1000 IU/2.5 mL 1500, 2500, 3000 IU/5 mL |